Three or four thousand words a month, written by the people who actually sign the Airway Bill — not a content agency in a different continent. Regulatory pathways, cold-chain breakage, documentation that survives customs — the stuff procurement teams wish someone had written down.
Every post is 1,800–2,400 words, written in-house, and covers a real question our desk has been asked more than once.
Every batch entering Germany passes through a Sachkundige Person under §15 AMG. What the QP checks in your Batch Manufacturing Record, which documents travel with the container, and where Indian manufacturers lose eight weeks.
Which route fits a 24-hour, five-day or 14-day window, and the paperwork plus CoA flags that matter for each. Tier 2 versus Tier 3 on the DHSC register and what that means for a hospital oncology desk.
KEMSA, NMS, MSD, CMS, EPSS and the FMoH each structure their oncology RFQs differently. What the bid document is actually asking for, and the four lines that separate a winning response from an also-ran.
Temperature mapping, transport qualification, batch traceability — the paperwork a UK hospital QA reviewer will ask to see before the first PO, and how an Indian exporter stands the audit up in a day.
Section by section, what MHRA, EDQM and GCC-DR reviewers look at first — from 3.2.S.4.4 batch analysis to 3.2.P.8 stability — and the common omissions that stall a filing by six months.
Fixed-cost economics, API supply chain, and what the gap between European-origin and Indian WHO-GMP bortezomib means for a 2025–2026 tender desk running a five-year contract.
What a first NHS named-patient request actually looks like end-to-end — the MHRA notification fields, the QP release letter, the cold-chain pre-shipment validation, and the three places the chain most often breaks.
Specials is an unlicensed medicine made against a prescription under Regulation 167; parallel import is a licensed EU medicine re-entered under a PLPI. When procurement uses which, and where the paperwork diverges.
Lead-country selection, local authorised-representative nomination, variation cascades, and the catches the brochure leaves out — including what to do when one of the six states rejects a centrally-approved dossier.
Tarmac dwell, generator-run warehouses, the NAFDAC inspection queue, and the three logger readings that decide whether a vaccine batch passes or fails at release.
The Indian export documentation chain from COPP to Certificate of Origin. What importers really need in the binder — and the four missing papers that stall 80% of first-time shipments.
If there's a regulatory pathway, customs process or documentation question you wish someone would explain properly, send it over. We'll write the next one about exactly that.
Suggest a topic →